Iron Citrate (Synthesit) Supplementation During Pancreas Cancer Showed Surprising Results – Case Study

1. Ponka P. Cellular iron metabolism. Kidney Int 1999; 55: 2–11. PonkaP. Cellular iron metabolism Kidney Int 1999 55 2 11 Search in Google Scholar

2. Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H. Iron metabolism and iron supplementation in cancer patients [published correction appears in Wien Klin Wochenschr 2015 Dec; 127 (23–24): 920–1]. Wien Klin Wochenschr 2015; 127 (23–24): 907–19. LudwigH EvstatievR KornekG AaproM BauernhoferT Buxhofer-AuschV FridrikM GeisslerD GeisslerK GisslingerH KollerE KopetzkyG LangA RumpoldH SteurerM KamaliH LinkH. Iron metabolism and iron supplementation in cancer patients [published correction appears in Wien Klin Wochenschr 2015 Dec; 127 (23–24): 920–1] Wien Klin Wochenschr 2015 127 23–24 907 19 Search in Google Scholar

3. Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013; 24: 1886–92. LudwigH MüldürE EndlerG HüblW Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia Ann Oncol 2013 24 1886 92 Search in Google Scholar

4. Ludwig H, Müldür E, Endler G, Hübl W, Moneuse P, Klement B. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96 (Suppl 2): 409. LudwigH MüldürE EndlerG HüblW MoneuseP KlementB. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status Haematologica 2011 96 Suppl 2 409 Search in Google Scholar

5. John Hopkins Medicine [Internet]. Pancreatic Cancer Prognosis; [cited 2023 Nov 07]. Available from: http://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis John Hopkins Medicine [Internet] Pancreatic Cancer Prognosis [cited 2023 Nov 07]. Available from: http://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis Search in Google Scholar

6. Cancer Treatment Centers of America [Internet]. Pancreatic cancer stages; [updated 2022 May 10; cited 2023 Nov 07]. Available from https://www.cancercenter.com/cancer-types/pancreatic cancer/stages#:~:text=Most%20often%2C%20pancreatic%20cancer%20spreads,Abdominal%20pain Cancer Treatment Centers of America [Internet] Pancreatic cancer stages [updated 2022 May 10; cited 2023 Nov 07]. Available from https://www.cancercenter.com/cancer-types/pancreatic cancer/stages#:~:text=Most%20often%2C%20pancreatic%20cancer%20spreads,Abdominal%20pain Search in Google Scholar

7. Cipora E, Czerw A, Partyka O, Pajewska M, Badowska-Kozakiewicz A, Fudalej M, Sygit K, Kaczmarski M, Krzych-Fałta E, Jurczak A, Karakiewicz-Krawczyk K, Wieder-Huszla S, Banaś T, Bandurska E, Ciećko W, Kosior DA, Kułak P, Deptała A. Quality of Life in Patients with Pancreatic Cancer-A Literature Review. Int J Environ Res Public Health 2023; 20 (6): 4895. CiporaE CzerwA PartykaO PajewskaM Badowska-KozakiewiczA FudalejM SygitK KaczmarskiM Krzych-FałtaE JurczakA Karakiewicz-KrawczykK Wieder-HuszlaS BanaśT BandurskaE CiećkoW KosiorDA KułakP DeptałaA Quality of Life in Patients with Pancreatic Cancer-A Literature Review Int J Environ Res Public Health 2023 20 6 4895 Search in Google Scholar

8. Jiang S, Fagman JB, Ma Y, Liu J, Vihav C, Engstrom C, Liu B, Chen C. A comprehensive review of pancreatic cancer and its therapeutic challenges. Aging (Albany NY) 2022; 14 (18): 7635–49. JiangS FagmanJB MaY LiuJ VihavC EngstromC LiuB ChenC. A comprehensive review of pancreatic cancer and its therapeutic challenges Aging (Albany NY) 2022 14 18 7635 49 Search in Google Scholar

9. Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer 2016; 57: 10–22. ConroyT BachetJB AyavA HuguetF LambertA CaramellaC MaréchalR Van LaethemJL DucreuxM. Current standards and new innovative approaches for treatment of pancreatic cancer Eur J Cancer 2016 57 10 22 Search in Google Scholar

10. Manji GA, Olive KP, Saenger YM, Oberstein P. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clin Cancer Res 2017; 23: 1670–8. ManjiGA OliveKP SaengerYM ObersteinP. Current and Emerging Therapies in Metastatic Pancreatic Cancer Clin Cancer Res 2017 23 1670 8 Search in Google Scholar

11. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002; 95 (4 Suppl): 912–22. OettleH RiessH. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer Cancer 2002 95 4 Suppl 912 22 Search in Google Scholar

12. Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013; 30 (1): 361. GunturuKS YaoX CongX ThumarJR HochsterHS SteinSM LacyJ. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity Med Oncol 2013 30 1 361 Search in Google Scholar

13. Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 2012; 65 (1): 9–22. GrazianiG TentoriL NavarraP. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer Pharmacol Res 2012 65 1 9 22 Search in Google Scholar

14. Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? Front Oncol 2020; 10: 576399. JiangB ZhouL LuJ WangY LiuC YouL GuoJ. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? Front Oncol 2020 10 576399 Search in Google Scholar

15. Li HY, Qi WL, Wang YX, Meng LH. Covalent inhibitor targets KRas^G12C: A new paradigm for drugging the undruggable and challenges ahead. Genes Dis 2021; 10 (2): 403–14. LiHY QiWL WangYX MengLH. Covalent inhibitor targets KRas^G12C: A new paradigm for drugging the undruggable and challenges ahead Genes Dis 2021 10 2 403 14 Search in Google Scholar

16. Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20 (37): 13343–68. LiuSX XiaZS ZhongYQ. Gene therapy in pancreatic cancer World J Gastroenterol 2014 20 37 13343 68 Search in Google Scholar

17. Hubbard JM, Grothey A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs 2017; 77: 1091–103. HubbardJM GrotheyA. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor Drugs 2017 77 1091 103 Search in Google Scholar

18. Pfister C, Schoenemann J. Selenium in Cancer Rehabilitation-A Retrospective Study from a Specialized Clinic. Nutrients 2023; 15 (17): 3827. PfisterC SchoenemannJ. Selenium in Cancer Rehabilitation-A Retrospective Study from a Specialized Clinic Nutrients 2023 15 17 3827 Search in Google Scholar

19. Lener MR, Scott RJ, Wiechowska-Kozłowska A, Serrano-Fernández P, Baszuk P, Jaworska-Bieniek K, Sukiennicki G, Marciniak W, Muszyńska M, Kładny J, Gromowski T, Kaczmarek K, Jakubowska A, Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat 2016; 48 (3): 1056–64 LenerMR ScottRJ Wiechowska-KozłowskaA Serrano-FernándezP BaszukP Jaworska-BieniekK SukiennickiG MarciniakW MuszyńskaM KładnyJ GromowskiT KaczmarekK JakubowskaA LubińskiJ Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer Cancer Res Treat 2016 48 3 1056 64 Search in Google Scholar

20. Peng L, Liu X, Lu Q, Tang T, Yang Z. Vitamin E intake and pancreatic cancer risk: a meta-analysis of observational studies. Med Sci Monit 2015; 21: 1249–55. PengL LiuX LuQ TangT YangZ. Vitamin E intake and pancreatic cancer risk: a meta-analysis of observational studies Med Sci Monit 2015 21 1249 55 Search in Google Scholar

21. Stoyanov E, Mizrahi L, Olam D, Schnitzer-Perlman T, Galun E, Goldenberg DS. Tumor-suppressive effect of S-adenosylmethionine supplementation in a murine model of inflammation-mediated hepatocarcinogenesis is dependent on treatment longevity. Oncotarget 2017; 8 (62): 104772–84. StoyanovE MizrahiL OlamD Schnitzer-PerlmanT GalunE GoldenbergDS. Tumor-suppressive effect of S-adenosylmethionine supplementation in a murine model of inflammation-mediated hepatocarcinogenesis is dependent on treatment longevity Oncotarget 2017 8 62 104772 84 Search in Google Scholar

22. Marley AR, Fan H, Hoyt ML, Anderson KE, Zhang J. Intake of methyl-related nutrients and risk of pancreatic cancer in a population-based case-control study in Minnesota. Eur J Clin Nutr 2018; 72 (8): 1128–35. MarleyAR FanH HoytML AndersonKE ZhangJ. Intake of methyl-related nutrients and risk of pancreatic cancer in a population-based case-control study in Minnesota Eur J Clin Nutr 2018 72 8 1128 35 Search in Google Scholar

23. Cencioni C, Trestini I, Piro G, Bria E, Tortora G, Carbone C, Spallotta F. Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches. Nutrients 2022; 14 (8): 1542. CencioniC TrestiniI PiroG BriaE TortoraG CarboneC SpallottaF. Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches Nutrients 2022 14 8 1542 Search in Google Scholar

24. Mitchell T, Clarke L, Goldberg A, Bishop KS. Pancreatic Cancer Cachexia: The Role of Nutritional Interventions. Healthcare (Basel) 2019; 7 (3): 89. MitchellT ClarkeL GoldbergA BishopKS. Pancreatic Cancer Cachexia: The Role of Nutritional Interventions Healthcare (Basel) 2019 7 3 89 Search in Google Scholar

25. Yakovenko A, Cameron M, Trevino JG. Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J Gastrointest Surg 2018; 10 (9): 95–106. YakovenkoA CameronM TrevinoJG. Molecular therapeutic strategies targeting pancreatic cancer induced cachexia World J Gastrointest Surg 2018 10 9 95 106 Search in Google Scholar

26. Yun BK, Song M, Hwang HK, Lee H, Lee SM, Kang CM, Lee SM. Potential Nutritional and Metabolomic Advantages of High Fat Oral Supplementation in Pancreatectomized Pancreaticobiliary Cancer Patients. Nutrients 2019; 11 (4): 893. YunBK SongM HwangHK LeeH LeeSM KangCM LeeSM. Potential Nutritional and Metabolomic Advantages of High Fat Oral Supplementation in Pancreatectomized Pancreaticobiliary Cancer Patients Nutrients 2019 11 4 893 Search in Google Scholar

27. Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Mori M, Doki Y. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Ann Surg Oncol 2018; 25 (7): 1868–79 MukaiY YamadaD EguchiH IwagamiY AsaokaT NodaT KawamotoK GotohK KobayashiS TakedaY TanemuraM MoriM DokiY. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy Ann Surg Oncol 2018 25 7 1868 79 Search in Google Scholar

28. Haase VH. The ins and outs of ferric citrate. Kidney Int 2022; 101 (4): 668–70. HaaseVH. The ins and outs of ferric citrate Kidney Int 2022 101 4 668 70 Search in Google Scholar

29. Hanudel MR, Czaya B, Wong S, Jung G, Chua K, Qiao B, Gabayan V, Ganz T. Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease. Sci Rep 2022; 12 (1): 6695. HanudelMR CzayaB WongS JungG ChuaK QiaoB GabayanV GanzT. Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease Sci Rep 2022 12 1 6695 Search in Google Scholar

30. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5. Am J Kidney Dis 2015; 65 (5): 728–36. BlockGA FishbaneS RodriguezM SmitsG ShemeshS PergolaPE WolfM ChertowGM. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5 Am J Kidney Dis 2015 65 5 728 36 Search in Google Scholar

31. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305 (23): 2432–9. IsakovaT XieH YangW XieD AndersonAH SciallaJ WahlP GutiérrezOM SteigerwaltS HeJ SchwartzS LoJ OjoA SondheimerJ HsuCY LashJ LeonardM KusekJW FeldmanHI WolfM Chronic Renal Insufficiency Cohort (CRIC) Study Group Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease JAMA 2011 305 23 2432 9 Search in Google Scholar

32. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91 (8): 3144–9. AntoniucciDM YamashitaT PortaleAA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men J Clin Endocrinol Metab 2006 91 8 3144 9 Search in Google Scholar

33. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011; 108 (46): E1146–1155. FarrowEG YuX SummersLJ DavisSI FleetJC AllenMR RoblingAG StayrookKR JideonwoV MagersMJ GarringerHJ VidalR ChanRJ GoodwinCB HuiSL PeacockM WhiteKE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice Proc Natl Acad Sci U S A 2011 108 46 E1146 1155 Search in Google Scholar